Clinical trial
A Phase 3 Randomized, Open-Label Multicenter Study to Evaluate Efficacy and Safety of Inebilizumab in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT07851220 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Open-Label Multicenter Study to Evaluate Efficacy and Safety of Inebilizumab in Adult Participants With Primary Membranous Nephropathy (PMN)
- Lead sponsor
- Amgen
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- October 1, 2026
- Completion date
- September 26, 2033
- Enrollment
- 159 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.